Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis

Abstract

Conclusion. These data suggest that the acceptable safety profile of etanercept therapy is maintained for up to 8 years in this population of JRA patients. Improvements in the signs and symptoms of JRA were also maintained for up to 8 years.Juvenile rheumatoid arthritis (JRA) is the most common rheumatic disease in children (1,2). JRA is typified by joint inflammation that can cause joint damage, retard normal growth, and lead to long-term disability and decreased quality of life (3,4). Traditional treatment of children with JRA includes the use of nonsteroidal antiinflammatory drugs (NSAIDs), corticoClinicalTrials.gov identifier: NCT00357903.

Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept

“…The introduction of biologics like etanercept had a major impact on the outcome of patients with polyarticular JIA. The safety and the efficiency of etanercept had been proved in open and controlled studies as well as in long term studies (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13).…”

New Treatment Strategies in the Treatment of Juvenile Idiopathic Arthritis

“…[31] The long-term safety profile of etanercept was maintained for up to eight years of continuous drug use. [32] Exposure-adjusted rates of SAEs did not increase over time, and the most common new SAEs reported beyond four years of drug exposure were flare or worsening of disease. Between the fourth and eighth year of follow-up, a single case of pyelonephritis was the only additional infection reported.…”

“…Etanercept has demonstrated sustained improvement in the signs and symptoms of polyarticular-course JIA with an acceptable safety profile in an open-label extension (OLE) of a RCT at four and eight years. [31,32] At an eight-year follow-up, an ACR Pedi 70 was achieved by 61% of patients.…”

EFFICACY OF ETANERCEPT TREATMENT AS a SECOND TNF Α INHIBITOR IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS AND PRIMARY AND SECONDARY INEFFICIENCY OR INTOLERANCE OF INFLIXIMAB

“…По данным D. J. Lovell и соавт. [32], в течение 8 лет терапии этанерцептом допустимое чис-ло нежелательных реакций не увеличивалось, тяжелых побочных реакций отмечено не было, а клиническое улучшение сохранялось у всех пациентов, продолжив-ших лечение.…”